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THE vascular supply of tumours labours under three serious disadvantages.
(1) The anatomnical peculiarities and inadequacy of newly formed vessels and
pre-existing vessels pressed into serving an ever-growing and greedy population of
tumour cells (Algire and Chalkley, 1945; Willis, 1953).
(2) The vessels have peculiarities of physiological function, being abnormally
sensitive to circulating hormones and to changes of blood pressure (Cater, Grigson
and Watkinson, 1962; Cater, Adair and Grove, 1966).
(3) There are factors present in tumours such as anoxia, necrosis, high tissue
pressure, infection likely to produce pathological changes in tumour vessels which
include inflammation, thrombosis and haemorrhage.
In the preceding paper Cater, Adair and Grove (1966) reported evidence from
oxygen tension measurements and the response to oxygen inhalation that certain
mediators of the inflammatory reaction, namely 5-hydroxytryptamine (5-HT),
bradykinin and kallikrein decreased tumour blood flow. In this paper the Pelikan
ink technique of Majno, Palade and Schoefl (1961), which outlines vessels under-
going the vascular permeability changes of inflammation, has been used to
study inflammatory changes in tumour vessels and in particular to answer two
questions.
(1) Would the untreated tumour have so many factors producing inflammation
that there would be widespread marking of the vessels?
(2) If " mediators " of the inflammatory reaction were injected into the circu-
lation would they produce inflammatory changes in tumour vessels with doses
not affecting normal tissues?
METHODS
Forty-seven August-strain rats (180-300 g.) were injected in the left thigh with
0.1 ml. suspension of transplantable hepatoma 223 cells (maintained as an ascites
tumour). When the tumours were 1 to 2 cm. in diameter (7 to 10 days after
transplantation) the rats were anaesthetised and injected into lateral tail vein with
Pelikan ink Cl1/1431a (Gunther Wagner, Pelikan Werke, Hanover, Germany)
1 ml./kg. rat. The average carbon particle size is 200 A, stabilised with 4-5 per
cent fish glue and containing 1-3 per cent phenol. Some tumour bearing rats
were used as controls, the others were treated with an inflammatory agent. In all
47 rats were used divided into 4 experimental groups.
* Gibb Fellow ofthe British Empire Cancer Campaign for Research.D. B. CATER AND C. R. TAYLOR
Series 1. 5-HT 5 mg. base/kg. i.p. (Serotonin creatine sulphate, Light & Co.).
Series 2. Bradykinin (B.R.S. 640, Sandoz) 2 /tg./kg./min. i.v. for 10 minutes
given by slow perfusion apparatus.
Series 3. Kallikrein (Glumorin, Bayer) 20 or 13 units/kg. i.m. or 0-1 to 1
unit/kg. i.v.
Series 4. Lysolecithin 0 5 to 25 mg./kg. i.v. (ex. egg lecithin crystals, Koch-
Light Labs Ltd.).
The first 18 rats were anaesthetised with ether. Then it was decided to give a
second dose of ink at 30 minutes and rats 19 to 47 (Series 3 and 4) were anaesthe-
tised with urethane. The inflammatory agent (or saline) wasinjected immediately
after the Pelikan ink. When a second injection ofink was given 0-02 ml. ofsaline
with 60 units heparin/ml. was injected after the first injection of ink or agent to
prevent clotting in the needle which was taped to the tail and left in situ with
syringe attached. The rats were left for an hour (or more) until the carbon was
cleared from their blood, as judged by their ears, feet and eyes regaining their
original pink colour. They were then killed under ether by the pneumothorax
technique of Majno and Palade (1961), the aorta and vena cava were clamped in
the abdomen, and the tumour leg, normal leg, diaphragm and some peritoneum
were placed in 10% formol saline for 14 days. The injection site was checked for
any spill of ink.
After 14 days tissue blocks were cut, given further fixation and cut in two.
One part was dehydrated and embedded in paraffin, the other part was washed
for 12 hours, put in 12.5% and 25% gelatine at 370 C. each for 24 hours and
embedded in 25% gelatine and refixed in formol saline. Frozen sections of the
gelatine blocks were cut at 25 and 50 ,u for preliminary examination ofthe vascular
pattern, and at 10 ,t for photomicrography. These sections were stained with
carmalum becausethismost clearly showedthe tumour structurewithout obscuring
the labelling. They were mounted in glycerine jelly.
RESULTS
Throughout the whole series ofexperiments there was remarkably little Pelikan
ink labelling of the vessels in normal muscle, even in those treated systemically
with an inflammatory agent. The tumours of the saline treated control animals
showed little variation in the 4 series of experiments except No. 19 to 23 which
were subcutaneous tumours with some necrosis and No. 40 to 47 which were
growing very rapidly. The answer to the first problem was that the control
tumour usually showed large areas with no labelling of the vessels. Vessels
marked with ink were seen only here and there but usually in association with
an obvious cause, a zone of necrosis, an area infiltrated with polymorphs or near
the margin of a cyst. However, there was a significant increase in the incidence
of labelled vessels in regions of active infiltration of muscle by malignant tumour
cells.
1. Effect of 5-HT (given i.p.) on tumour vessels and normal muscle
The results are summarised in Table I from which it will be seen that in the
animals given 5-HT (5 mg. base/kg. i.p.) there was an increased incidence in the
carbon labelling of the tumour vessels (both in number and extent), and an
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TABLE I.-Series 1. Effect of 5-HT (5 my. base/ikg. i.p. in saline 1 ml./lkg.)
on Inflammatory Changes in Tumour Vessels
Sites in
Amount of order of Pooling of blood in vessels
Experiment carbon label most carbon , I
Number Treatment of vessels labelling Below 30, Above 30,s
1 . Saline . + . peripheral (p.) . + +++
3 . Saline . + . 2 discrete foci . + + +
5 . Saline ± p. + +
7 . Saline . +4. p. . + + +
9 . Saline . + . p. & central focus FF+ + + +
11 . Saline . . .. . - + +
*24 . Saline . +4+ . in haemorrhagic zone + - +
*22t . Saline . +-+ . central + + +-+F+
2 . 5-HT . ++++ . p. & general . ++++ ++
4 . 5-HT . +++ . p. &central . ++++ +++
6 . 5-HT . ++++ . p. &;central ++++ +++
8 . 5-HT . + + + +. p. & general .+ + + + + +
10 . 5-HT F A+ + + +. p. & general . + + + + +
12 . 5-HT . +- + . p. & central . + + + +
*25 . 5-HT . ++-+ central & p. . + + + +A+
*27 . 5-HT . + + ++. central & p. .+ + + + + +
*23t . 5-HT . + ++. central . + + + + + +
* Received 2 doses of ink at 0 and 30 minutes.
t Tuniours situated in subcutaneous tissue offlank.
N.B. Normal muscle showed little or no carbon labelling; pooling of blood in vessels below
30z was +, above 30,u + + in both saline and 5-HT treated animals.
increased pooling of blood in vessels of less than 30 It diameter. Fig. 1 shows a
typical zone of control tumour with cells in mitosis but without significant carbon
labelling ofthe vessels, and Fig. 2 a comparable zone oftumour in a 5-HT treated
animal showing several vessels marked with carbon. Fig. 3 shows considerable
pooling of red cells in a labelled vessel in the tumour of a rat treated with 5-HT.
The pooling of blood in vessels less than 30It in diameter could be caused by
exudation from the vessels or by stasis following 5-HT induced contraction of
arterioles and venules. It was argued that, ifthe stasis was caused by exudation,
the ink from a single injection would probably have been cleared from the circula-
tion before the exudation was complete. Therefore, experiments using two injec-
tions of ink at 0 and 30 minutes were set up. These are marked * in the tables.
In fact, no obvious increase of tumour vessel marking either in saline controls or
animals treated with 5-HT was obtained after two injections of ink (Fig. 4), but
ink was sometimes seen mixed with the pooled blood in distended vessels (Fig. 5).
In our view the appearances favour vascular spasm as the cause ofthe stasis after
5-HT. The fact that vessels tend either to show carbon labelling or pooling is
confirmatory evidence.
2. Effect of bradykinin i.v. on tumour vessels and normal muscle
Again normal muscle vessels either in saline or bradykinin treated animals
showed little in the way of carbon labelling or stasis in vessels of less than 30 ,u.
The same was true of the tumour vessels of the saline treated controls. Fig. 6
shows a typical zone ofactively dividing tumour cells without any labelled vessels.
However, the tumours in the bradykinin treated rats showed vessels heavily
marked with carbon situated in nests oftumour cells. Fig. 7 is a typical zone and520 D. B. CATER AND C. R. TAYLOR
it will be seen that two cells in mitosis (a metaphase and an anaphase) are situated
quite close to the marked vessel. The vessels most affected were 15 to 30 ,t in
diameter, but those of capillary dimensions were sometimes marked (Fig. 8) where
the vessel outlined with carbon traces a course like a flattened omega for over
500 microns. Muscle not adjacent to tumour was clear of carbon. There was a
very real distinction between normal muscle, control tumour and bradykinin
treated tumour (Table II).
TABLE II.-Series 2. Effect ofBradlykinin 2 4ag. ikg./min. i.v.for
10 minutes on Inflammatory Changes in Tumour Vessels
Amount of Pooling of blood in vessels
Experiment carbon label Sites of most A -- a
Number Treatment in vessels carbon label Below 30,u Above 30M
13 Saline i peripheral (p.) . + +
15 Saline .. . .. ±+
14 . Bradykinin + + + gen. & p. + + + +
17 Bradykinin ++++ gen. . ++
18 . Bradykinin . + + + +. gen. & p. . + + + + +
3. Effect of kallikrein on tumour vessels and normal muscle
Sections of normal muscle from both saline injected controls and kallikrein
injected rats compare closely with those described for Series 1 and 2 and the control
tumours were similar to those described in these series except for No. 21 which
was growing in the subcutaneous tissue ofthe flank and had a rich vascularity and
some haemorrhage. The results are summarised in Table III; note that 19 to 21
were subcutaneous tumours and 44 to 47 were very rapidly growing tumours.
In animals given the big doses ofkallikrein i.m. carbon labelling ofthe tumour
vessels was more marked than in the controls and was more general in distribution
EXPLANATION OF PLATES
FIG. 1. Tran9Planted hepatoma of saline-injected control, there is no labelling of the vessels
with ink. The presence ofmitotic figures indicate growing tumour. Frozen section, stained
with Carmalum. x 148.
FIG. 2. Tumour of rat given 5-HT 5 mg. (base)/kg. i.p. immediately after Pelikan ink i.v.
There are several labelled vessels. Frozen section stained with Carmalum. x 148.
FIG. 3. 5-HT treated rat showing pooling of blood and labelling of vessel wall in tumour.
Frozen section, stained with Carmalum. x 148.
FIG. 4.-5-HT treated rat given a second dose of ink at 30 minutes. There is labelling of a
capillary and a vennule. Frozen section stained with Carmalum. x 160.
FIG. 5.-5-HT treated rat given a second dose of ink at 30 min., there is ink mixed with blood
in distended vessels in the tumour. Frozen section, stained with Carmalum. x 148.
FIG. 6.-Tumour from saline injected control rat for comparison with Fig. 7-12; a large zone
of actively growing tumour has no labelled vessels. Frozen section, stained Carmalum.
x60.
FIG. 7.-Tumour from rat treated with bradykinin; the labelled vessel is surrounded by
growing tumour; note the mitotic figures. Frozen section, stained Carmalum. x 148.
FIG. 8. Tumour from another rat treated with bradykinin; the labelled capillary can be
traced across the se3tion. Frozen section, stained Carmalum. x 160.
FIG. 9.-A zone of tumour infiltrating muscle and showing several labelled vessels, from a rat
given kallikrein 1 unit/kg. i.v. Frozen section, stained Carmalum. x 60.
FIG. 10.-A strand of tumour infiltrating muscle shows several labelled vessels, from a rat
given kallikrein 0-1 unit/kg. i.v. Frozen section, stained Carmalum. x 96.
FIG. 11.-Tumour showing labelled vessels from a rat given lysolecithin 5 mg./kg. i.v. Frozen
section, stained Carmalum. x 160.
FIG. 12.-A single labelled vessel in a narrow strand of tumour cells infiltrating muscle from a
rat given lysolecithin 5 mg. kg. i.v. Frozen section, stained with Carmalum. x 148.BRITISH JOURNAL OF CANCER.
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TABLE III.-Series 3. Effect ofKallikrein 0-1 to 20 i.u./kg. i.m. or i.v.
Amount of Sites of
Experiment carbon label mo
Number Treatment in vessels I
*21t . Saline . ++ . Cent.
*30 . Saline . + .
*46 . Saline .+
*19t . Kallikrein 20 + + +
units/kg. i.m.
*20t . Kallikrein 20 ++ + g
units/kg. i.m.
*29 . 13 units/kg. i.m.. + + + + g
*31 .13 units/kg. im.. + + + + g
*45 I unit/kg. i.v. . ++F . g
*44 0 5 units/kg. i.v. ++ g
*47 . 0 units/kg. i.v. + + +. g
* Received 2 doses of ink at 0 and 30 minutes.
t Tumour situated in subcutaneous tissue of flank.
st carbon
label
haem. zone
central
central
general
,eneral
reneral
,eneral
reneral
,eneral
seneral
Pooling of blood in vessels
Below 30/z Above 30,
++ -F±-
+ ±
++ ++~~F-
++
+++-
++
++
+
+
+
though still most pronounced in regions of infiltrating tumour. The results in
rats given 0.1 to 1 unit/kg. i.v. were more difficult to interpret. There was less
carbon labelling than in the animals given the much larger doses i.m., but there
was more than in the control tumours. Labelling was predominantly venular in
character. There was widespread haemorrhage, but this was not mixed with
carbon so that it must have taken place before the injection of ink or after it had
cleared from the circulation. Fig. 9 shows very beautiful carbon marking ofsmall
vessels in a zone of infiltrating tumour from a rat given kallikrein 1 unit/kg. i.v.
Fig. 10 illustrates the edge of the tumour in a rat given kallikrein 0 1 unit/kg. i.v.
and shows a strand of tumour with several labelled vessels, but the adjacent
muscle is free from carbon labelling of its vessels.
4. Effect of lysolecithin (i.v.) on tumour vessels and normal muscle
Sections of normal muscle from both saline injected controls and lysolecithin
injected rats were similar to those described in Series 1, 2 and 3. Control tumours
were also similar to the control tumours of the previous series, except that No. 40
was very rapidly growing and had areas ofhaemorrhage and some carbon labelling.
The data shown inTable IVindicate some increased carbonlabelling inthe tumours
of the lysolecithin treated rats and pooling of blood in the small vessels. Carbon
was also present in zones of haemorrhage indicating that the basement membrane
of vessels had been disrupted. In zones where blood had pooled in vessels the
red cells were tightly compacted, suggesting an early stage ofcoagulation. Carbon
labelling was quite well marked and, though vessels of 15-20 It were affected, there
was increased labelling of those less than 15 It in diameter. The tumour from
rat 37 injected with lysolecithin 5 mg./kg. i.v. shows considerable carbon labelling
ofboth large and small vessels (Fig. 11). Fig. 12 (from rat 36 given the same dose
of lysolecithin) shows a labelled vessel in a narrow band of tumour infiltrating
muscle. In rats given 0 5 to 2 mg./kg. i.v. of lysolecithin the observed effects
decreased, dense pooling suggestive of coagulation was seen in places but the
incidence of carbon labelling was not much greater than in the controls. The
higher doses oflysolecithin all produced haemoglobinuria, doses of 0 5 to 2mg./kg.
did not. The doses of lysolecithin used may have been less than those quoted
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TABLE IV.-Series 4. Effect of Lysolecithin 0.5 to 25 mg./lkg. i.v. on
Inflammatory Changes in Tumour Vessels
Amount of Sites of Pooling of blood in vessels
Experiment carbon label most carbon A-
Number Treatment in vessels label Below 30, Above 30u
*33 Saline + a single focus + + + +
*39 Saline ++ central . + + + +
*40 Saline + + area of haemorrhage,. + + + +
*32 . Lysolecithin 25 + + + . peripheral (p) + + + + +
*34 . , . +H+ . general +++ ++
*35 .H --, , + + + P. HH ++
*36 5 mg./kg. i.v. + + +. cent. & gen. + + + +
*37 . ,,,,,,. + + + central + + + + +
*38 H-H-- ,, + + P +H-H-H-H
*42 . 2 mg./kg. i.v. . +H- general ++H+ +H+-+
*43 1 mg./kg. i.v. . +H- general . + + + +
*41 . 0-5mg./kg. i.v. H+- p. H+-+ +H+
* Received 2 doses of ink at 0 and 30 minutes.
N.B. The doses of lysolecithin may have been less than stated as emulsification in saline was
probably not complete.
as it was realised afterwards that the lysolecithin and the saline should have been
titurated more thoroughly in a mortar until a milky solution was obtained.
DISCUSSION
In the Majno, Palade and Schoefl technique Pelikan ink injected i.v. leaks
through the endothelium of inflamed vessels but is arrested by the intact base-
ment membrane thusoutlining vessels where inflammatory exudation is occurring.
In this investigation we used this technique to answer two questions.
(1) Would the untreated tumours have so many factors producing inflammation
that there would be widespread carbon marking of vessels?
(2) Ifmediators ofthe inflammatory reaction were injected into the circulation
would the tumour vessels pick these up and become inflamed with doses which did
not affect normal tissues?
The answer to problem one is that some vessels in the control tumours showed
carbon labelling but the number ofvessels labelled and the extent of the labelling
was less in the control tumours than in the tumours of rats treated systemically
with inflammatory agents. Also, in the control tumours marked vessels were
frequently near to zones of necrosis, haemorrhage, polymorphonuclear infiltration
or cysts. However, zones where tumour cells were actively infiltrating muscle
often showed carbon labelled vessels.
The answer to problem two is that 5-HT (5 mg. base/kg., i.p.), bradykinin
(2/ug./kg./min., i.v. for 10 minutes), kallikrein (not less than 1 unit/kg., i.v.)
and lysolecithin (not less than 2 mg./kg., i.v.) all increased the number of tumour
vessels which showed carbon labelling. Pooling of blood in vessels of less than
15 ,u diameter was also a common feature ofthe tumours of rats treated systemati-
cally with the inflammatory agents. Normal muscle of both control and treated
animals showed virtually no marking of the vessels.
There were some differences in the effects produced by the different inflam-
matory agents. Thus 5-HT tended to produce carbon labelling of some vessels
andpooling in others. Vesselsshowingpoolingwereusuallyunmarked. EvidenceTUMOUR VASCULARITY AND INFLAMMATORY MEDIATORS
from measurements of oxygen tension in tumour and the response when the animal
breathes oxygen often indicated complete circulatory stasis in tumours after this
dose of 5-HT (Cater, Grigson and Watkinson, 1962; Cater, Schoeniger and
Watkinson, 1963). Could this stasis be due to inflammatory exudation from the
tumour vessels proceeding to the stage that the vessels become blocked by a solid
mass of red cells, or did 5-HT produce stasis by causing constriction of arterioles
and venules? We argued that if 5-HT stasis was due to exudation this would not
be complete by the time one injection of Pelikan ink had been cleared from the
circulation-about 30 minutes and that a second dose of ink should increase the
labelling. On the other hand ifthe 5-HT stasis was due to vasospasm then it was
likely to be complete inside 30 minutes and a second dose ofink should not increase
the number and extent oflabelled vessels. In fact, we found that the second dose
of ink did not increase the number of marked vessels. If our reasoning is correct
this is in favour ofvasospasm. Also some vessels with no ink against the basement
membrane now showed ink mixed with the solid mass of red cells in vessels full of
pooled blood. This is also in favour of 5-HT producing stasis by vasospasm.
The evidence from the oxygen-tension measurements indicated that stasis had
occurred within 20 minutes ofinjection of 5-HT and this is in favour ofvasospasm.
The salient feature of bradykinin treated rats was the presence of carbon
labelled venules (and some capillaries) in the middle of zones of dividing tumour
cells, with cells in mitosis quite close to the marked vessels. Had the carbon
labelled vessels been near to necrotic tumour the finding would have been of little
significance, but finding labelled vessels in the zones of active growth argues in
favour of the effect being real and important.
Kallikrein would be expected to produce results similar to bradykinin. Lewis
(1964) and Miles (1964) have reviewed the activation of prokallikrein and its
subsequent kininogenic activity. The inactive precursor of kallikrein, present in
blood, is activated by contact with certain foreign substances, a sequence in which
the Hageman factor has an acknowledged role. Activated kallikrein enzymatically
hydrolyses anx2 globulin substrate to form plasma kinin which is closely similar
to bradykinin, if not identical. Recent evidence suggests that several kinins
are produced including bradykinin (Lewis, 1964). The kinins produced may
include those which lyse clots and basement membranes.
Cotran and Majno (1964) distinguished four types of vascular leakage. (1)
The immediate-type, coming on early in inflammation but transient, and the
carbon labelling is predominantly venular. Histamine, 5-HT, bradvkinin,
permeability-factor and lactic acid all mimic the immediate response.
(2) The delayed-type, causing a prolonged exudation, and the carbon-labelling
is mainly in the capillaries with some involvement of the arterioles and venules.
The delayed response could be due to slow liberation of bradykinin and other
kinins insitu by the action of kallikrein, but the capillary localisation is against
this.
(3) Direct vascular injury following severe trauma which involves all types
of vessels.
(4) Leakage from regenerating capillaries (Schoefl, 1964).
The effect of lysolecithin on tumour vessels was studied because Fischer and
Haupt (1961) claimed that in some forms of injury complement activity may
release lysolecithin. Cotran and Majno (1964b) injected lysolecithini into the
cremaster muscle of the rat and found definite carbon labelling of the capillaries
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as well as of the venules, especially if the Pelikan ink was injected 2 hours after
lysolecithin. They therefore think that lysolecithin might be an important factor
in the delayed-type ofinflammatory exudate. Fischer (1964) found that antigen/
antibody complexes plus complement damaged the oxygen utilisation of ascites
tumour cells. He assumed that the activated complement was equivalent to
lysolecithin. Butterworth and Cater (as yet unpublished) have found that Ivso-
lecithin per se does damage the oxygen uptake of Ehrlich ascites tumour cells and
BP8 ascites tumour cells. Thus lysolecithin could damage the tumour cells and
the damage result in inflammatory changes, but it is much more likely that the
carbon labelling observed was due to direct damage of the vascular endothelium
by the lysolecithin. We also found some evidence suggestive of agglutination of
red cells. It is possible that we would have obtained more labelling ofthe tumour
vessels if we had injected the Pelikan ink 1 to 2 hours after the lysolecithin.
The dosage/response effect of lysolecithin would repay further study.
It is pertinent to enquire why inflammatory agents given systemically should
affect tumour vessels more than those of normal tissues. There are a number of
possible explanations:
(1) Tumour vessels could be simply a special case of a general principle that all
newly formed vessels are unduly susceptible to inflammatory agents. Schoefi
(1964) found that the tips of new capillary buds leaked ink and in his experiments
they had not been subjected to deliberate damage. In fact experiments are
planned in which a direct comparison of tumour vessels with those in granulation
tissue will be possible and their relative sensitivities to inflammatory agents
studied.
(2) The damage of tumour vessels by inflammatory agents could be due to
anatomical flaws inherent in their rapid formation. Algire and Chalkley (1945)
watched sarcomatransplants grow in transparent chambers and found that tumour
blood vessels originated from host capillary buds, as in granulation tissue, but
their rate of growth far exceeded that in granulation tissue.
(3) The damage of tumour vessels by inflammatory agents could be due to the
slow blood flow in dilated tumour vessels. The low oxygen tension in tumour
argues in favour of low blood flow or high oxygen utilisation by the cells. The
dye injection experiments of Goldacre and Sylven (1959, 1962) and Owen (1960)
indicate a poor blood flow especially in the central parts of tumours. The direct
measurements by Gullino and Grantham (1961, 1962) of the blood flow in " tissue
isolated transplants" indicated a very low blood flow in tumour. A low blood
flow would allow time for the inflammatory agent to become localised. By
comparison, in resting muscle a large proportion ofthe capillaries would be closed.
(4) Another possibility is that many of the tumour vessels are already in a
state of subliminal inflammation, because of anoxia and the proximitv of necrotic
or damaged cells, and thus require only minimal quantities of inflammatory
agents to produce demonstrable inflammatory exudation. This hypothesis
would not explain the bradykinin effect where the labelled vessels were in good.
actively growing tumour. It would only explain carbon labelling of vessels
near some obvious cause of inflammation.
(5) The damage of tumour vessels by inflammatory agents could be due to
certain conditions in tumour which produce vicious circles. We think these may
be very important in tumours. For instance, the low oxygen tension often present
in a tumour would inhibit the activity ofmono-amine oxidase, ifthis enzyme were
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important in the destruction of 5-HT, then the destruction of 5-HT in tumour
would be delayed even if the tumour contained a normal quantity of the enzyme.
Or consider the case of bradykinin this is quickly destroyed in the blood by
kininases, but Edery and Lewis (1963) showed that at slightly lower pH values
kininase is inhibited without any slowing of the production of kallikrein. The
direct measurements ofVoegtlin, Kahler and Fitch (1935) and Kahler and Robert-
son (1943) showed that tumours have a lower pH than normal tissues and that
injection of glucose can lower this still further by production of lactic acid. Thus
the destruction of bradykinin might well be slower in tumour than in normal
tissue. This may also be true, to a greater or lesser extent, of granulation tissue.
The list of substances of physiological and pathological importance to which
tumour vessels are abnormally sensitive now includes adrenaline, noradrenaline,
acetyl choline (Cater, Adair and Grove, 1966), 5-HT, bradykinin, kallikrein,
lysolecithin and Shear's polysaccharide (Shear, 1941 ; Shear and Perrault, 1944).
This aspect of tumour physiology/pathology merits further investigation.
SUMMARY
Rats with hepatomas transplanted in thigh were injected i.v. with Pelikan ink
(colloidal carbon which labels inflamed vessels) and immediately afterwards either
saline or an inflammatory agent was given systemically. The tumours of saline-
injected control rats showed some labelled vessels situated peripherally and near
necrotic or haemorrhagic zones. The inflammatory agents 5-HT, bradykinin,
kallikrein and lysolecithin given systemically increased the labelling ofvessels in
zones of growing tumour. Muscle vessels were not labelled in controls or rats
given inflammatory agents.
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